This CME initiative is designed to meet the educational needs of urologists, medical oncologists, oncology nurses, and other health care providers involved in the treatment of patients with prostate cancer.

This CME initiative is designed to meet the educational needs of urologists, medical oncologists, oncology nurses, and other health care providers involved in the treatment of patients with prostate cancer.

This initiative is designed to meet the educational needs of oncologists, oncology pharmacists, oncology nurses and other healthcare professionals and teams involved in the management of patients with cancer who are treated or eligible for treatment with immunotherapy.

This CME initiative is designed to meet the educational needs of urologists, medical oncologists, oncology nurses, and other health care providers involved in the treatment of patients with prostate cancer.

This CME initiative is designed to meet the educational needs of urologists, medical oncologists, oncology nurses, and other health care providers involved in the treatment of patients with prostate cancer.

This live activity is focused on the care of patients with early HER2-positive breast cancer.

This initiative is designed to meet the educational needs of oncologists, oncology pharmacists, oncology nurses and other healthcare professionals and teams involved in the management of patients with cancer who are treated or eligible for treatment with immunotherapy.

This live activity will cover the treatment and management of patients with metastatic, hormone receptor-positive, HER-2 negative breast cancer.

This live activity will cover the treatment and management of patients with metastatic colorectal cancer.

This live activity will review newly approved and investigational agents and combinations of agents that may improve outcomes for patients with relapsed, refractory follicular lymphoma (FL). Traditionally, FL has been associated with the development of aggressive disease and poor outcomes for many patients. The ongoing development of new compounds with unique mechanisms of action extends the available treatment options for patients across all lines of therapy, with an emphasis on personalization of care.

This initiative is designed to meet the educational needs of ER physicians and hematologist-oncologists involved in the treatment of patients with hemophilia.

This live activity will cover the treatment and management of patients with bladder cancer.